诊断后12个月内早期生物治疗可提高克罗恩病透壁愈合率
这项多中心回顾性研究纳入154例开始生物治疗的成人克罗恩病患者,用磁共振小肠造影评估治疗后12±6个月的透壁愈合。诊断后12个月内早期启动生物治疗与透壁愈合率显著升高相关(aOR 3.23,95%CI 1.36-7.70,P<.01),透壁愈合与肠道损伤进展、手术和升级治疗风险降低相关。
要点
- 诊断后12个月内启动生物治疗与透壁愈合率显著升高相关(aOR 3.23)。
- 透壁愈合与肠道损伤进展风险降低相关(aHR 0.28)。
- 透壁愈合与克罗恩病相关手术风险降低相关(aHR 0.21)。
核心结论
- 诊断后12个月内早期启动生物治疗显著提高克罗恩病患者的透壁愈合率,并带来更好的长期结局。
研究设计与样本
- 多中心回顾性研究,纳入154例开始生物治疗的成人克罗恩病患者。
- 透壁愈合用磁共振小肠造影在开始治疗后12±6个月评估,影像由盲法专家放射科医生审阅。
- 透壁愈合定义为所有磁共振小肠造影参数完全正常化。
- 生物治疗启动时机作为连续变量分析,最佳截断值用约登指数和临床相关性确定。
- 采用逻辑回归及倾向评分校正分析评估早期生物治疗与透壁愈合的关联,并评估长期结局。
主要发现
- 154例患者中,诊断后12个月内早期生物治疗与透壁愈合率显著升高相关(aOR 3.23;95%CI 1.36-7.70;P<.01)。
- 校正既往生物治疗使用后该关联持续存在(aOR 2.82;95%CI 1.13-7.06;P=.03)。
- 透壁愈合与肠道损伤进展风险降低相关(aHR 0.28;95%CI 0.10-0.79;P=.02)。
- 透壁愈合与克罗恩病相关手术风险降低相关(aHR 0.21;95%CI 0.05-0.88;P=.03)。
- 透壁愈合与治疗升级风险降低相关(aHR 0.35;95%CI 0.14-0.88;P=.02),且独立于早期生物治疗。
关键数值与推荐
- 透壁愈合定义为磁共振小肠造影所有参数完全正常化。
- 早期生物治疗定义为诊断后12个月内启动。
- 透壁愈合评估时间为开始治疗后12±6个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Transmural healing (TH) is emerging as a potential Crohn's disease (CD) treatment target. Early biological treatment seems to be associated with improved disease outcomes, but its impact on TH remains unclear. We aimed to assess the impact of early biological treatment initiation on TH and its influence on CD prognosis. METHODS: This multicenter retrospective study included adult patients with CD starting biological therapy. TH was assessed using magnetic resonance enterography (MRE) at 12 ± 6 months post-therapy initiation, with radiological examinations reviewed by blinded expert radiologists. TH was defined as complete normalization of all MRE parameters. Timing of biological therapy initiation was analyzed as a continuous variable, with optimal cutoff determined using the Youden index and clinical relevance. Logistic regression with propensity score-adjusted analysis was used to assess the association between early biological therapy initiation and TH. Long-term outcomes (bowel damage progression, CD-related surgery, CD-flare hospitalization, and therapy escalation) were evaluated. RESULTS: Among 154 patients with CD, early biological therapy initiation within 12 months of diagnosis was associated with significantly higher TH rates (adjusted odds ratio [aOR], 3.23; 95% confidence interval [CI], 1.36-7.70; P < .01), which persisted after adjusting for previous biological therapy use (aOR, 2.82; 95% CI, 1.13-7.06; P = .03). Time-to-event analysis demonstrated that TH was significantly associated with reduced risk of bowel damage progression (adjusted hazard ratio [aHR], 0.28; 95% CI, 0.10-0.79; P = .02), CD-related surgery (aHR, 0.21; 95% CI, 0.05-0.88; P = .03) and therapy escalation (aHR, 0.35; 95% CI, 0.14-0.88; P = .02), independently of early biological therapy. CONCLUSIONS: Early initiation of biological therapy within 12 months of diagnosis significantly increases TH rates, leading to improved long-term outcomes in patients with CD.
引用
- Revés J, Fernandez-Clotet A, Ordás I, et al. Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn's Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39209193. doi:10.1016/j.cgh.2024.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。